Effective therapies for Hodgkin's disease have been available for over 30 years (Rosenberg, 1989) . These therapeutic successes have been based on a combination and integration of better diagnostic methods to evaluate the extent of the disease (lymphography, diagnostic laparotomy with splenectomy, bone marrow biopsy and computerised tomography), of technical advancements in radiotherapy (supervoltage machines and linear accelerators, allowing the delivery of tumoricidal doses to well identified lymphoid fields) and the development of combination chemotherapy, particularly MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) (De Vita et al., 1965 , 1980 Bonadonna, 1982; Rosenberg, 1989) . Still, availability and utilisation of curative treatments is not homogeneous and a summary tabulation of overall age-standardised mortality from the disease in various European geographic areas for the period 1978-82 has shown elevated rates in several Central and Eastern European countries (Yugoslavia, Switzerland, Czechoslovakia) , with a 3-to 5-fold difference compared with the lower rate areas in France and Denmark (Levi et al., 1989) .
It was decided, therefore, to further investigate trends in Hodgkin's disease in Europe, and to present in this paper details of trends in each separate country and selected age groups.
Materials and methods
Death certification numbers for Hodgkin's disease, stratified for sex and 5 year age groups for 30 European countries (excluding the Soviet Union and a few small countries like Malta, Liechtenstein, etc.), were derived from copies of the original computer tapes of the World Health Organisation (WHO) database. During the calendar period considered , four different Revisions of the International Classification of Diseases (ICD) were used, but there were no changes in the definition or coding of the disease between various Revisions.
Estimates of the resident population, generally based on official Censuses, were obtained from the same WHO databank. From the matrices of certified deaths and resident populations age-standardised rates (using the World Standard Population) were computed (Doll & Smith, 1982) . Besides overall age-adjusted rates, four different (age-standardised) truncated rates (0-14, 15-34, 35-64 and 65 and over) were chosen for presentation.
In a few countries, data were missing for part of the calendar period. When a single year was missing within a quinquennium, numerators and denominators were interpolated linearly from the previous and subsequent calendar year. No extrapolation was made for missing data at the beginning or the end of the calendar period considered, or when data on one or more quinquennia were not available.
For countries covered by national cancer registration schemes, mortality rates were contrasted with incidence trends, derived from subsequent volumes of 'Cancer Incidence in Five Continents' (Doll et al., 1966 (Doll et al., , 1970 Waterhouse et al., 1976 Waterhouse et al., , 1982 Muir et al., 1988) .
Results
Trends in mortality from Hodgkin's disease are presented in Figure 1 for Western Europe and in Figure 2 for Eastern Europe in males and females of all ages and in two separate age groups (0-34 and 35-64 years). Rates for the first (usually 1955-59) and last (usually 1985-88) calendar period, together with the corresponding average absolute number of deaths per year and per cent changes, were further tabulated in Table I for population of all ages, in Table II  for children under age 15 and in Table III in the oldest age  group (65 years and over) .
In all western countries there were substantial declines in mortality. The declines in all age mortality from Hodgkin's disease between the late 1950s and the mid 1980s were around the overall mean of 50% in both sexes (Table I) and most countries, except for Nordic Countries (and particularly Denmark and Sweden, whose fall approached 70%), and Portugal, Spain and Greece (with falls between 20 and 30%).
These declines tended to start between the late 1960s and the early 1970s in most countries, and were evident both in aAge-standardised rates on the world standard population. b198084. cLess than one death per year. It is unlikely that problems of diagnosis and certification of Hodgkin's disease (particularly with respect to non-Hodgkin's lymphomas) (Gruffermann & Delzell, 1986; Glaser & Swartz, 1990) , which might have somewhat influenced the rates, could explain the observed trends. The pathological entity of Hodgkin's disease, with its pathognomonic ReedSternberg cell, has been recognised for almost a century now (Reed, 1902; Sternberg, 1893; Hellmann, 1991) . In relation to these potential problems, it is also reassuring that the pattern of trends, in most countries, was similar at younger and middle age, when diagnosis and certification of the disease has long been more accurate (Doll & Peto, 1981) .
A further support to the existence of a major role of therapy, rather than diagnostic artifacts, on these trends comes from a comparison of incidence and mortality rates for European Community Members States in 1980-84, since incidence rates were two to three times higher than the corresponding mortality, the differences being greater in younger ages (Jensen et al., 1990 ). In the early 1980s, the differences between incidence and mortality were systematic- ally smaller in areas covered by cancer registration from Eastern Europe (Levi et al., 1989 Serraino et al., 1991) . This may well influence survival rates, but is unlikely to largely explain the mortality trends observed. Registered mortality trends were less consistent above age 65, but this is compatible with generalised decline in reliability and validity of cancer death certification in the elderly (Doll & Peto, 1981) . In addition, experience from all countries indicates that the prognosis for elderly patients with Hodgkin's disease remains poor, despite clear improvements in therapy. Still, this is less important for Hodgkin's disease than for epithelial cancers, since Hodgkin's disease incidence does not rise with a power of age (Cook et al., 1969; Doll, 1971) , and the proportion of cases in the elderly is consequently smaller than for epithelial neoplasms.
The major determinant of the favourable trends in mortality in Western Europe has been improved treatment of the disease, as confirmed also by comparison of incidence and mortality trends in selected areas. These clear successes notwithstanding, the present data gives scope for a few critical considerations. First, advancements in radiotherapy have been available since the 1950s, and effective chemotherapy in clinical series from research settings has been available since the early 1960s (De Vita et al., 1965; Rosenberg, 1989) . Only from the late 1960s or early 1970s onwards, however, improvements became evident in national mortality data from more advanced western European countries, and in a few countries rates started to fall only during the late 1970s. This is consisted with a modelling of survival data from the US (Cairns & Boyle, 1983; Boyle et al., 1988; La Vecchia et al., 1989) . This figure could well approach 4000 deaths avoided per year if the larger advancements observed in a few Scandinavian countries had been registered in other western European countries, too. 1965 1970 1975 1980 1960 1965 1970 1975 1980 1965 1970 1975 1980 1960 1965 1970 1975 1980 Even within Western Europe, there is certainly scope for future progress, as indicated by the different patterns of trends in various countries and by the observation that rates are still downwards in most recent periods in most areas.
A major indication emerging from this analysis, moreover, is on the importance and urgency of improving the availability of currently defined knowledge and resources for the treatment of Hodgkin's disease, as well as of other types of curable cancers (Boyle et al., 1990) , in Central and Eastern Europe.
Further study in these countries will determine whether the major problem relates to a failure to refer patients for treatment at specialised cancer centres, where the results of treatment for curable neoplasms such as Hodgkin's disease may be expected to be superior to those in non-specialist centres. An alternative explanation could be the lack of availability of certain cytotoxic agents, and this would be particularly regrettable, as the drugs involved have been widely used for several years.
